Adaptive Biotechnologies Corporation Statistics
Share Statistics
Adaptive Biotechnologies Corporation has 147.58M shares outstanding. The number of shares has increased by 1.86% in one year.
| Shares Outstanding | 147.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.07% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 142.73M |
| Failed to Deliver (FTD) Shares | 376 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 8.96M, so 6.07% of the outstanding shares have been sold short.
| Short Interest | 8.96M |
| Short % of Shares Out | 6.07% |
| Short % of Float | 6.28% |
| Short Ratio (days to cover) | 9.71 |
Valuation Ratios
The PE ratio is -3.14 and the forward PE ratio is -6.31.
| PE Ratio | -3.14 |
| Forward PE | -6.31 |
| PS Ratio | 4.15 |
| Forward PS | 4.5 |
| PB Ratio | 2.29 |
| P/FCF Ratio | -4.24 |
| PEG Ratio | n/a |
Enterprise Valuation
Adaptive Biotechnologies Corporation has an Enterprise Value (EV) of 871.85M.
| EV / Earnings | -3.87 |
| EV / Sales | 5.12 |
| EV / EBITDA | -4.61 |
| EV / EBIT | -3.84 |
| EV / FCF | -5.22 |
Financial Position
The company has a current ratio of 4.66, with a Debt / Equity ratio of 0.45.
| Current Ratio | 4.66 |
| Quick Ratio | 4.5 |
| Debt / Equity | 0.45 |
| Total Debt / Capitalization | 31.23 |
| Cash Flow / Debt | -1.12 |
| Interest Coverage | -16.45 |
Financial Efficiency
Return on equity (ROE) is -0.73% and return on capital (ROIC) is -42.22%.
| Return on Equity (ROE) | -0.73% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -42.22% |
| Revenue Per Employee | 240.16K |
| Profits Per Employee | -317.70K |
| Employee Count | 709 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 5.23 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 29.16% in the last 52 weeks. The beta is 1.45, so Adaptive Biotechnologies Corporation's price volatility has been higher than the market average.
| Beta | 1.45 |
| 52-Week Price Change | 29.16% |
| 50-Day Moving Average | 5.34 |
| 200-Day Moving Average | 4.14 |
| Relative Strength Index (RSI) | 56.21 |
| Average Volume (20 Days) | 1.21M |
Income Statement
In the last 12 months, Adaptive Biotechnologies Corporation had revenue of $170.28M and earned -$225.25M in profits. Earnings per share was $-1.56.
| Revenue | 170.28M |
| Gross Profit | 94.72M |
| Operating Income | -227.03M |
| Net Income | -225.25M |
| EBITDA | -189.27M |
| EBIT | -227.03M |
| Earnings Per Share (EPS) | -1.56 |
Balance Sheet
The company has $65.06M in cash and $229.43M in debt, giving a net cash position of -$164.37M.
| Cash & Cash Equivalents | 65.06M |
| Total Debt | 229.43M |
| Net Cash | -164.37M |
| Retained Earnings | -1.14B |
| Total Assets | 558.51M |
| Working Capital | 220.72M |
Cash Flow
In the last 12 months, operating cash flow was -$156.32M and capital expenditures -$10.70M, giving a free cash flow of -$167.02M.
| Operating Cash Flow | -156.32M |
| Capital Expenditures | -10.70M |
| Free Cash Flow | -167.02M |
| FCF Per Share | -1.16 |
Margins
Gross margin is 55.63%, with operating and profit margins of -133.33% and -132.29%.
| Gross Margin | 55.63% |
| Operating Margin | -133.33% |
| Pretax Margin | -132.32% |
| Profit Margin | -132.29% |
| EBITDA Margin | -111.16% |
| EBIT Margin | -133.33% |
| FCF Margin | -98.09% |
Dividends & Yields
ADPT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -24.8% |
| FCF Yield | -17.98% |
Analyst Forecast
The average price target for ADPT is $6.5, which is 3.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.5 |
| Price Target Difference | 3.3% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -1.85 |
| Piotroski F-Score | 3 |